Adherence to Subcutaneous Biological Therapies in Patients with Inflammatory Rheumatic Diseases and Inflammatory Bowel Disease: A Systematic Review

References

• Maniadakis N , TothE , SchiffMet al. A targeted literature review examining biologic therapy compliance and persistence in chronic inflammatory diseases to identify the associated unmet needs, driving factors, and consequences. Adv. Ther.35(9), 1333–1355 (2018).
   PubMed Web of Science ®Google Scholar
• Baumgart DC , MiseryL , NaeyaertS , TaylorPC. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities?Front. Pharmacol.10, 279 (2019).
   PubMed Web of Science ®Google Scholar
• World Heath Organization . Adherence to long-term therapies: evidence for action. www.who.int/chp/knowledge/publications/adherence_report/en/
   Google Scholar
• Bluett J , MorganC , ThurstonLet al. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford)54(3), 494–499 (2015).
   PubMed Web of Science ®Google Scholar
• Brown MT , BussellJK. Medication adherence: WHO cares?Mayo Clin. Proc.86(4), 304–314 (2011).
   PubMed Web of Science ®Google Scholar
• López-González R , LeónL , LozaE , RedondoM , GarciaDe Yébenes MJ , CarmonaL. Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review. Clin. Exp. Rheumatol.33(4), 559–569 (2015).
   PubMed Web of Science ®Google Scholar
• Michetti P , WeinmanJ , MrowietzUet al. Impact of treatment-related beliefs on medication adherence in immune-mediated inflammatory diseases: results of the global ALIGN study. Adv. Ther.34(1), 91–108 (2017).
   PubMed Web of Science ®Google Scholar
• Cea-Calvo L , CarmonaL , Calvo-AlenJ. The challenge of assessing adherence to subcutaneous biological drugs in immune-mediated inflammatory diseases. Letter to the editor regarding Michetti P, Weinman J, Mrowietz U et al. Adv. Ther.34(9), 2173–2176 (2017).
   PubMed Web of Science ®Google Scholar
• Cramer JA , RoyA , BurrellAet al. Medication compliance and persistence: terminology and definitions. Value Health11(1), 44–47 (2008).
   PubMed Web of Science ®Google Scholar
• Vrijens B , DeGeest S , HughesDAet al. A new taxonomy for describing and defining adherence to medications. Br. J. Clin. Pharmacol.73(5), 691–705 (2012).
   PubMed Web of Science ®Google Scholar
• Hoy D , BrooksP , WoolfAet al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J. Clin. Epidemiol.65(9), 934–939 (2012).
   PubMed Web of Science ®Google Scholar
• Ottawa Hospital Research Institute . WellsGA , SheaB , O’ConnellDet al.The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. www.ohri.ca/programs/clinical_epidemiology/oxford.asp
   Google Scholar
• Liberati A , AltmanDG , TetzlaffJet al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ339, b2700 (2009).
   PubMed Web of Science ®Google Scholar
• Bhoi P , BessetteL , BellMJ , TkaczykC , NantelF , MaslovaK. Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database. BMJ Open7(9), e015872 (2017).
   PubMed Web of Science ®Google Scholar
• Borah BJ , HuangX , ZarotskyV , GlobeD. Trends in RA patients’ adherence to subcutaneous anti-TNF therapies and costs. Curr. Med. Res. Opin.25(6), 1365–1377 (2009).
   PubMed Web of Science ®Google Scholar
• Calip GS , AdimadhyamS , XingS , RinconJC , LeeWJ , AnguianoRH. Medication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditions. Semin. Arthritis Rheum.47(2), 157–164 (2017).
   PubMed Web of Science ®Google Scholar
• Calvo-Alen J , VelaP , BustabadS , MaceirasF , CarmonaL , Cea-CalvoL. Satisfaction, fulfillment of expectations and adherence to subcutaneous biological drugs in patients with rheumatoid arthritis: ARCO study. Reumatol. Clin.16(2 Pt 1), 116–119 (2020).
   PubMed Web of Science ®Google Scholar
• Cea-Calvo L , RayaE , MarrasCet al. The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern. Rheumatol. Int.38(9), 1735–1740 (2018).
   PubMed Web of Science ®Google Scholar
• Gendelman O , WeitzmanD , RosenbergV , ShalevV , ChodickG , AmitalH. Characterization of adherence and persistence profile in a real-life population of patients treated with adalimumab. Br. J. Clin. Pharmacol.84(4), 786–795 (2018).
   PubMed Web of Science ®Google Scholar
• Govani SM , NoureldinM , HigginsPDRet al. Defining an optimal adherence threshold for patients taking subcutaneous anti-TNFs for inflammatory bowel diseases. Am. J. Gastroenterol.113(2), 276–282 (2018).
   PubMed Web of Science ®Google Scholar
• Harley CR , FrytakJR , TandonN. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am. J. Manag. Care9(Suppl. 6), S136–S143 (2003).
   PubMed Web of Science ®Google Scholar
• Haydek J , ShahN , SlaughterJC , AlE. Non-adherence to self-injectable biologic medication in patients with moderate to severe inflammatory bowel disease is associated with increased healthcare resource utilization. Gastroenterology156(6), S–414 (2019).
   Web of Science ®Google Scholar
• Khilfeh I , GuyetteE , WatkinsJ , DanielsonD , GrossD , YeungK. Adherence, persistence, and expenditures for high-cost anti-inflammatory drugs in rheumatoid arthritis: an exploratory study. J. Manag. Care Spec. Pharm.25(4), 461–467 (2019).
   PubMed Web of Science ®Google Scholar
• Mena-Vazquez N , Manrique-ArijaS , Yunquera-RomeroLet al. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study. Rheumatol. Int.37(10), 1709–1718 (2017).
   PubMed Web of Science ®Google Scholar
• Oton T , CarmonaL , Urruticoechea-AranaA , Calvo-AlenJ , ArteagaMJ , Cea-CalvoL. Discordance between doctor and patient assessments and non-adherence to subcutaneous biological drugs. Rheumatol. Int.39(6), 1077–1082 (2019).
   PubMed Web of Science ®Google Scholar
• Srulovici E , GargV , GhilaiAet al. Is patient support program participation associated with longer persistence and improved adherence among new users of adalimumab? A retrospective cohort study. Adv. Ther.35(5), 655–665 (2018).
   PubMed Web of Science ®Google Scholar
• Wang L , LeongR. IDDF2018-ABS-0026 Persistence and adherence of anti-tumour necrosis factor (TNF) biologics for inflammatory bowel disease (IBD) in Australia. Gut67, A298 (2018).
   PubMed Web of Science ®Google Scholar
• Wentworth BJ , BuerleinRCD , TuskeyAG , OverbyMA , SmolkinME , BehmBW. Nonadherence to biologic therapies in inflammatory bowel disease. Inflamm. Bowel Dis.24(9), 2053–2061 (2018).
   PubMed Web of Science ®Google Scholar
• Tkacz J , EllisL , BolgeSC , MeyerR , BradyBL , RuetschC. Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients. Clin. Ther.36(5), 737–747 (2014).
   PubMed Web of Science ®Google Scholar
• Wolf DC , JaganathanS , BurudpakdeeCet al. Adherence rates and health care costs in Crohn’s disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data. Patient Prefer. Adherence12, 869–878 (2018).
   PubMed Web of Science ®Google Scholar
• Vogelzang EH , HebingRCF , NurmohamedMTet al. Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up. PLoS ONE13(10), e0205125 (2018).
   PubMed Web of Science ®Google Scholar
• Kiltz U , PeterlikD , WinkelmannV , TonyH-P. AB0705 Aquila study in Germany – real world adherence and persistence of secukinumab treatment in ankylosing spondylitis and psoriatic arthritis patients – an interim analysis. Ann. Rheum. Dis.78(Suppl. 2), 1814–1815 (2019).
   Google Scholar
• Santoleri F , SoriceP , LasalaR , RizzoRC , CostantiniA. Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis. J. Med. Econ.17(5), 320–325 (2014).
   PubMedGoogle Scholar
• Hilliquin P , BarnetcheT , BaudensG , NiarraR , IdierI , SarauxA. Subcutaneous tocilizumab in monotherapy or in combination with DMARD in patients with moderate to severe active rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months, interim analysis. Arthritis Rheumatol.70(Suppl. 9), 621–622 (2018).
   Google Scholar
• Morgan C , McbethJ , CordingleyLet al. The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatology (Oxford)54(10), 1780–1791 (2015).
   PubMed Web of Science ®Google Scholar
• Salaffi F , CarottiM , DiCarlo M , FarahS , GutierrezM. Adherence to anti-tumor necrosis factor therapy administered subcutaneously and associated factors in patients with rheumatoid arthritis. J. Clin. Rheumatol.21(8), 419–425 (2015).
   PubMed Web of Science ®Google Scholar
• Horne R , AlbertA , BooneC. Relationship between beliefs about medicines, adherence to treatment, and disease activity in patients with rheumatoid arthritis under subcutaneous anti-TNF alpha therapy. Patient Prefer. Adherence12, 1099–1111 (2018).
   PubMed Web of Science ®Google Scholar
• Nisar MK , MirzaW , RafiqA , EisenhutM. Adherence to biologic therapy: does it vary with ethnicity?Biologicals54, 28–32 (2018).
   PubMed Web of Science ®Google Scholar
• Alañón Pardo M , DelÁguila VA , DíazJCet al. CP-104 Adherence to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Eur. J. Hosp. Pharm.23(Suppl. 1), A45–A46 (2016).
   Google Scholar
• Bruna-Barranco I , AlarconP , LuéAet al. P524 Active smoking and personal concerns about treatment can impair adherence to adalimumab in inflammatory bowel diseases: a prospective evaluation. J. Crohns Colitis12(Suppl. 1), S371–S371 (2018).
   Google Scholar
• van der Have M , OldenburgB , KapteinAAet al. Non-adherence to anti-TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre study. J. Crohns Colitis10(5), 549–555 (2016).
   PubMed Web of Science ®Google Scholar
• Saez Bello M , LlopisSalvia P , AlegreSancho JJ , ParedesArquiola JM , AsencioMunoz MDC , ClimenteMarti M. Clinical utility of serum concentrations of adalimumab as predictor of treatment adherence. Reumatol. Clin.16(1), 32–37 (2020).
   PubMed Web of Science ®Google Scholar
• Calvo-Alen J , MonteagudoI , SalvadorGet al. Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study. Clin. Exp. Rheumatol.35(3), 423–430 (2017).
   PubMed Web of Science ®Google Scholar
• Feldman CH , LiiJ , GopalakrishnanC , FranklinJM , KimSC. THU0664 Treatment adherence to conventional and biologic disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Ann. Rheum. Dis.77(Suppl. 2), 526–526 (2018).
   Google Scholar
• Smith T , HarnettJ , GrubenD , ChenC , AgarwalE , WoolcottJ. Real-world experience with tofacitinib versus adalimumab and etanercept in biologic-naive patients with RA previously treated with methotrexate: data from a US administrative healthcare insurance claims database. Arthritis Rheumatol.69(Suppl. 10), (2017). https://acrabstracts.org/abstract/real-world-experience-with-tofacitinib-versus-adalimumab-and-etanercept-in-biologic-naive-patients-with-ra-previously-treated-with-methotrexate-data-from-a-us-administrative-healthcare-insurance-clai/
   Google Scholar
• Levy RA , TeichV , FernandesRet al. Patient support program for adalimumab-treated patients in Brazil: impact on patients’adherence and persistence. Arthritis Rheumatol.68(Suppl. 10), (2016). https://acrabstracts.org/abstract/patient-support-program-for-adalimumab-treated-patients-in-brazil-impact-on-patients-adherence-and-persistence/
   PubMedGoogle Scholar
• Oelke KR , ChambenoitO , MajjhooAQ , GrayS , HigginsK , HurP. Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database. J. Comp. Eff. Res.8(8), 607–621 (2019).
   PubMed Web of Science ®Google Scholar
• Brixner D , RubinDT , MeasePet al. Patient support program increased medication adherence with lower total health care costs despite increased drug spending. J. Manag. Care. Spec. Pharm.25(7), 770–779 (2019).
   PubMed Web of Science ®Google Scholar
• Stolshek BS , WadeS , MutebiA , DeAP , WadeRL , YeawJ. Two-year adherence and costs for biologic therapy for rheumatoid arthritis. Am. J. Manag. Care24(8 Spec No.), SP315–SP321 (2018).
   PubMed Web of Science ®Google Scholar
• Bonafede M , JohnsonBH , TangDH , HarrisonDJ , StolshekBS. Compliance and cost of biologic therapies for rheumatoid arthritis. Am. J. Pharm. Benefits9(5), 84–90 (2017).
   Google Scholar
• Accortt NA , SchenfeldJ , ChangE , PapoyanE , BroderMS. Changes in healthcare utilization after etanercept initiation in patients with rheumatoid arthritis: a retrospective claims analysis. Adv. Ther.34(9), 2093–2103 (2017).
   PubMed Web of Science ®Google Scholar
• Chu LH , KawatkarAA , GabrielSE. Medication adherence and attrition to biologic treatment in rheumatoid arthritis patients. Clin. Ther.37(3), 660–666e668 (2015).
   PubMed Web of Science ®Google Scholar
• Degli Esposti L , SangiorgiD , PerroneVet al. Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study. Clinicoecon. Outcomes Res.6, 401–407 (2014).
   PubMedGoogle Scholar
• Li P , BlumMA , Von FeldtJ , HennessyS , DoshiJA. Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. Value Health13(6), 805–812 (2010).
   PubMed Web of Science ®Google Scholar
• Li L , CuiY , YinRet al. Medication adherence has an impact on disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Patient Prefer. Adherence11, 1343–1356 (2017).
   PubMed Web of Science ®Google Scholar
• Khan S , RupniewskaE , NeighborsM , SingerD , ChiarappaJ , ObandoC. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J. Clin. Pharm. Ther.44(4), 495–507 (2019).
   PubMed Web of Science ®Google Scholar
• Kane S , HuoD , AikensJ , HanauerS. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am. J. Med.114(1), 39–43 (2003).
   PubMed Web of Science ®Google Scholar
• Perry J , ChenA , KariyawasamVet al. Medication non-adherence in inflammatory bowel diseases is associated with disability. Intest. Res.16(4), 571–578 (2018).
   PubMedGoogle Scholar
• Simpson SH , EurichDT , MajumdarSRet al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ333(7557), 15 (2006).
   PubMed Web of Science ®Google Scholar
• Karlsson SA , EliassonB , FranzenS , MiftarajM , SvenssonAM , AnderssonSundell K. Risk of cardiovascular event and mortality in relation to refill and guideline adherence to lipid-lowering medications among patients with Type 2 diabetes mellitus in Sweden. BMJ Open Diabetes Res. Care7(1), e000639 (2019).
   PubMed Web of Science ®Google Scholar
• Pasma A , SchenkC , TimmanRet al. Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment? PLoS ONE 12(2), e0171070 (2017).
   PubMed Web of Science ®Google Scholar
• Chan W , ChenA , TiaoD , SelingerC , LeongR. Medication adherence in inflammatory bowel disease. Intest. Res.15(4), 434–445 (2017).
   PubMed Web of Science ®Google Scholar
• Doyle C , LennoxL , BellD. A systematic review of evidence on the links between patient experience and clinical safety and effectiveness. BMJ Open3(1), e001570 (2013).
   PubMed Web of Science ®Google Scholar
• Foot H , LaCaze A , GujralG , CottrellN. The necessity-concerns framework predicts adherence to medication in multiple illness conditions: a meta-analysis. Patient Educ. Couns.99(5), 706–717 (2016).
   PubMed Web of Science ®Google Scholar
• Vangeli E , BakhshiS , BakerAet al. A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv. Ther.32(11), 983–1028 (2015).
   PubMed Web of Science ®Google Scholar
• Coleman CI , LimoneB , SobierajDMet al. Dosing frequency and medication adherence in chronic disease. J. Manag. Care Pharm.18(7), 527–539 (2012).
   PubMed Web of Science ®Google Scholar
• Shah NB , HaydekJ , SlaughterJet al. Risk factors for medication nonadherence to self-injectable biologic therapy in adult patients with inflammatory bowel disease. Inflamm. Bowel Dis.26(2), 314–320 (2020).
   PubMed Web of Science ®Google Scholar